Table 4.

Adverse Reactions During Treatment of the 27 Patients

Adverse Reactions	Grade 1	Grade 2	Grade 1 + 2	Grade 3	Grade 4	Grade 3 + 4
Leukopenia	20(74.1%)	3(11.1%)	23(85.2%)	1(3.7%)	0(0%)	1(3.7%)
Neutropenia	18(66.7%)	6(22.2%)	24(88.9%)	0(%)	0(0%)	0(0%)
Thrombocytopenia	14(51.9%)	2(7.4%)	16(59.3%)	0(%)	0(0%)	0(0%)
Anemia	7(25.9%)	10(37.1%)	17(63.0%)	1(3,7%)	0(0%)	1(%)
Nausea or Vomiting	22(81.5%)	5(18.5%)	27(100.0%)	0(0%)	0(0%)	0(0%)
Fever	5(18.5%)	5(18.5%)	10(37.0%)	0(0%)	0(0%)	0(0%)
Hypothyroidism	12(44.5%)	4(14.9%)	16(59.3%)	0(0%)	0(0%)	0(0%)
Muscle or joint pain	7(25.9%)	1(3.7%)	8(28.6%)	0(0%)	0(0%)	0(0%)
Hepatic dysfunction	12(44.5%)	8(29.6%)	20(74.1%)	0(0%)	0(0%)	0(0%)
Interstitial pneumonia	0(0%)	1(3.7%)	1(3.7%)	0(0%)	0(0%)	0(0%)
Peripheral sensory neurotoxicity	18(66.7%)	3(11.1%)	21(77.8%)	0(0%)	0(0%)	0(0%)
Weakness	15(55.6%)	2(7.4%)	17(63.0%)	0(0%)	0(0%)	0(0%)
Rash	2(7.4%)	1(3.7%)	3(11.1%)	0(0%)	0(0%)	0(0%)
Hair loss	3(11.1%)	0(0%)	3(11.1%)	0(0%)	0(0%)	0(0%)